In a patient with acute decompensated heart failure and stage 2 chronic kidney disease (eGFR ≈ 60–89 mL/min), should furosemide or metolazone be used first‑line, and what is the recommended dosing strategy?

Furosemide First-Line in ADHF with Stage 2 CKD

In acute decompensated heart failure with stage 2 CKD (eGFR 60–89 mL/min), furosemide is the first-line diuretic; metolazone should only be added if the patient fails to respond to moderate-to-high dose loop diuretics (>240 mg IV furosemide daily). 1, 2, 3

Initial Diuretic Strategy

Loop diuretics—specifically IV furosemide—are the cornerstone of decongestion in ADHF across all stages of kidney function 1, 2, 3. With stage 2 CKD (eGFR 60–89 mL/min), renal function is relatively preserved, making loop diuretics highly effective as monotherapy.

Starting dose:

• Diuretic-naive patients: 20–40 mg IV furosemide as a single slow push (over 1–2 minutes) 4
• Chronic loop diuretic users: 1–2 times the total daily oral dose given IV 1, 4

If inadequate response within 1–2 hours, double the dose and reassess 1, 4. The goal is to achieve brisk diuresis (net negative fluid balance ≥1000 mL/day or weight loss ≥1 kg/day) 5.

When to Escalate to Combination Therapy

Metolazone should be reserved for patients who remain congested despite moderate-to-high dose loop diuretics (defined as >240 mg IV furosemide daily or equivalent) 6, 3. This is critical because:

• Stage 2 CKD patients typically respond well to loop diuretics alone 7—the eGFR threshold where loop diuretic efficacy substantially declines is around 30 mL/min, not 60–89 mL/min 7
• Combination diuretics markedly increase risk of electrolyte depletion (hypokalemia, hypomagnesemia, hyponatremia) and azotemia 1, 2
• Recent evidence shows that in patients with eGFR >30 mL/min, metolazone provides additional natriuresis benefit, but this advantage is only clinically meaningful when loop diuretics have been pushed to adequate doses first 7

Metolazone Dosing (If Needed)

If escalation is required:

• Start with 2.5–5 mg PO once daily in combination with the loop diuretic 1, 2, 8
• Administer metolazone 30–60 minutes before the loop diuretic dose to maximize sequential nephron blockade 1
• Monitor electrolytes and renal function closely—check within 24–48 hours after initiation, then every 5–7 days 9
• Maximum dose is typically 10–20 mg daily, though most patients respond to ≤5 mg 8, 10

Critical Monitoring Parameters

Before adding metolazone, verify:

• Serum potassium ≥4.0 mEq/L (replete if low) 1
• Serum sodium >125 mEq/L 10
• No signs of volume depletion (hypotension, rising creatinine without congestion) 1

After adding metolazone:

• Daily weights and strict intake/output monitoring
• Electrolytes (K, Mg, Na) and creatinine every 1–2 days initially 9
• Watch for hypokalemia <2.5 mEq/L or hyponatremia <125 mEq/L, which occur in ~10% of treatment episodes 10

Common Pitfalls

1. Adding metolazone too early: Many clinicians add thiazides before adequately escalating loop diuretics. In stage 2 CKD, push furosemide to at least 80–160 mg IV before considering combination therapy 1, 3.

2. Ignoring volume status: If creatinine rises >30% without persistent congestion signs (elevated JVP, edema, orthopnea), this suggests volume depletion, not diuretic resistance—reduce diuretics, don't add more 1, 6.

3. Inadequate electrolyte monitoring: The risk of severe hypokalemia increases 4-fold with combination diuretics 1. Ensure ACE inhibitors/ARBs and aldosterone antagonists are optimized to mitigate potassium loss, but avoid potassium-sparing diuretics during acute combination therapy initiation 1, 9.

4. Forgetting GDMT optimization: Diuretics treat symptoms, not the underlying pathophysiology. Ensure neurohormonal blockade (ACE-I/ARB/ARNI, beta-blockers, MRAs, SGLT2 inhibitors) is initiated or up-titrated during hospitalization to prevent recurrent decompensation 3, 11.

Alternative Escalation Strategy

If loop diuretic resistance persists despite high doses:

• Continuous IV furosemide infusion (40 mg IV load, then 10–40 mg/hour) may be more effective than bolus dosing 1, 6
• Acetazolamide 500 mg IV once daily added to furosemide has shown benefit in recent trials, though evidence is stronger in more advanced CKD 12

Prognosis and Outcomes

Patients with stage 2 CKD who develop diuretic resistance have 4-fold higher odds of prolonged hospitalization (>4 days) and increased risk of worsening renal function 13, 5. However, baseline eGFR 60–89 mL/min predicts favorable response to diuretics compared to more advanced CKD 14, 7. NT-proBNP >1000 pg/mL at admission is the strongest predictor of diuretic resistance (sensitivity 81%, specificity 80%) 5.